Adaptimmune Reports Q1 2024 Financial and Business Updates
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024
Afami-Cel在公司投資者日發佈了商業和監管最新情況（在此重播）；FDA的審查和檢查正在進行中，PDUFA的日期爲2024年8月4日
Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval
商業和製造基礎設施到位，可在獲得批准後支持 afami-cel 的商業推出
Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO
來自使用 afami-cel 的 SPEARHEAD-1 關鍵試驗的數據發表於 《柳葉刀》；來自計劃在ASCO上公佈的關鍵lete-cel IGNYTE-ESO試驗的中期分析的數據
Cash runway into late 2025
直到 2025 年底的現金流道
Conference call today at 8 a.m. EDT webcast link HERE
美國東部時間今天上午8點的電話會議網絡直播鏈接在這裏
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) today.
賓夕法尼亞州費城和英國牛津--（Newsfile Corp.，2024年5月15日）——重新定義細胞療法治療實體瘤癌的公司Adaptimmune Therapeutics plc（納斯達克股票代碼：ADAP）今天公佈了截至2024年3月31日的第一季度財務業績和業務最新情況。該公司將於今天美國東部時間上午 8:00（英國夏令時間下午 1:00）舉辦網絡直播。
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "Support from the sarcoma community continues to highlight the high unmet medical need for new therapies for synovial sarcoma and we are making great progress preparing for the commercial launch of afami-cel on approval. Behind afami-cel, we plan to launch lete-cel for synovial sarcoma and MRCLS in 2026 with projected peak US sales of $400 million for our sarcoma franchise."
阿德里安·羅克利夫， Adaptimmune 首席執行官： “肉瘤界的支持繼續凸顯出對滑膜肉瘤新療法的高度未得到滿足的醫療需求，我們正在爲afami-cel獲得批准的商業上市做準備取得長足的進展。在afami-cel背後，我們計劃在2026年推出用於滑膜肉瘤的lete-cel和MRCLS，預計我們的肉瘤系列在美國的峯值銷售額爲4億美元。”
Sarcoma Franchise with afami-cel and lete-cel
afami-cel 和 lete-cel 的肉瘤特許經營權
- U.S. FDA accepted the BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024
- The BLA mid-cycle review meeting was held with FDA in April
- FDA GCP Bioresearch Monitoring Program (BIMO) inspections have been conducted at Adaptimmune and at selected clinical sites that participated in the pivotal
SPEARHEAD-1 trial - FDA GMP Pre-license inspections (PLI) have taken place at the Company's Navy Yard facility and at the lentiviral vector contract manufacturer's facility
- Preliminary plans for confirmatory evidence for afami-cel's full approval were previously agreed with FDA, including Cohort 2
- Adaptimmune expects to discuss post-marketing requirements and commitments at the late-cycle meeting which is scheduled for the second half of May
- To date, the FDA has not requested an Advisory Committee meeting or a REMS program
- The marketing application for the companion diagnostic for MAGE-A4 is currently under FDA review and is expected to be approved contemporaneously with the BLA
- Adaptimmune is preparing to launch afami-cel on approval in the U.S. Initially, launch will be focused on 6-10 selected treatment centers ("Authorized Treatment Centers" or "ATCs") and will expand to up to ~30 ATCs.
- 100% of the customer facing commercial and medical affairs teams is now in place
- Company launched : an unbranded website aimed at educating healthcare providers about TCR T-cell therapy in solid tumors, including synovial sarcoma, and the role of biomarkers and testing to determine future treatments
- The second product in Adaptimmune's sarcoma franchise, lete-cel, is being investigated in the pivotal IGNYTE-ESO trial (NCT03967223), which at a planned interim analysis exhibited response in 18/45 of patients (ORR 40%). The primary efficacy endpoint requires 16/60 patients have responses, so this trial has met its primary endpoint for efficacy. The full pivotal analyses are anticipated in late 2024.
- Lete-cel will enable Adaptimmune to expand its addressable synovial sarcoma patient population by targeting the NY-ESO cancer antigen, in addition to MAGE-A4 targeted by afami-cel, as well as treating Myxoid Round Cell Liposarcoma (MRCLS) patients.
- Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million
-
Data presentations
- Data from pivotal SPEARHEAD-1 trial with afami-cel published in The Lancet: article entitled "Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial"
- Data from the planned interim analysis of the pivotal IGNYTE-ESO trial with lete-cel to be presented by Dr. Sandra P. D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, in an oral presentation at ASCO entitled "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" during the Developmental Therapeutics-Immunotherapy session in Hall D2 on June 3, 2024 at 11:30 a.m. CDT
- 美國食品藥品管理局接受了用於治療晚期滑膜肉瘤的 afami-cel 的 BLA，優先審查，PDUFA 日期爲 2024 年 8 月 4 日
- BLA週期中期審查會議於4月與美國食品和藥物管理局舉行
- FDA GCP 生物研究監測計劃 (BIMO) 已在 Adaptimmune 和參與關鍵檢查的特定臨床場所進行了檢查
SPEARHEAD-1 試用版 - FDA GMP 許可前檢查 (PLI) 已在該公司的海軍造船廠和慢病毒載體合同製造商的工廠進行
- 此前已與美國食品藥品管理局商定了爲afami-cel獲得全面批准提供確證證據的初步計劃，包括隊列2
- Adaptimmune預計將在定於5月下半月舉行的週期末會議上討論上市後的要求和承諾
- 迄今爲止，美國食品和藥物管理局尚未要求召開諮詢委員會會議或REMS計劃
- MAGE-A4 伴隨診斷的上市申請目前正在接受美國食品藥品管理局的審查，預計將與BLA同時獲得批准
- Adaptimmune正準備在美國獲得批准後推出afami-cel。最初，將重點推出6-10個選定的治療中心（“授權治療中心” 或 “ATC”），並將擴大到最多約30個ATC。
- 面向客戶的商業和醫療事務團隊現已全部到位
- 公司推出：一個無品牌的網站，旨在教育醫療保健提供者了解包括滑膜肉瘤在內的實體瘤的TCR T細胞療法，以及生物標誌物和測試在確定未來治療方法方面的作用
- 在關鍵的IGNYTE-ESO試驗（NCT03967223）中，Adaptimmune肉瘤系列中的第二款產品lete-cel正在研究中，該試驗（計劃中的中期分析）顯示18/45名患者（ORR 40％）出現反應。主要療效終點要求16/60名患者有反應，因此該試驗已達到其主要療效終點。完整的關鍵分析預計將在2024年底完成。
- Lete-Cel 將使 Adaptimmune 能夠通過靶向 NY-ESO 癌症抗原以及 afami-cel 靶向的 MAGE-A4 以及治療粘液圓形細胞脂肪肉瘤（MRCLS）患者來擴大其可尋址的滑膜肉瘤患者群體。
- afami-cel和lete-cel的肉瘤特許經營權利用了相同的開發和商業足跡，預計美國旺季銷售額將高達4億美元
-
數據演示
- 來自 afami-cel 的關鍵 SPEARHEAD-1 試驗的數據發表在《柳葉刀》上：文章標題爲”用於晚期滑膜肉瘤和粘液樣圓細胞脂肪肉瘤（SPEARHEAD-1）的Afamitresgene autoleucel：一項國際開放標籤的2期試驗”
- 計劃對使用lete-cel的關鍵IGNYTE-ESO試驗進行中期分析的數據，將由紀念斯隆·凱特琳癌症中心肉瘤內科腫瘤醫學博士桑德拉·德安傑洛博士在ASCO的口頭髮言中公佈，題目是”滑膜肉瘤或粘液樣/圓細胞脂肪肉瘤患者中的Lete-cel：計劃對關鍵的IGNYTE-ESO試驗進行中期分析” 中部夏令時間 2024 年 6 月 3 日上午 11:30 在 D2 大廳舉行的發育療法-免疫療法會議上
Clinical pipeline
臨床管道
- Uzatresgene autoleucel ("uza-cel", formerly ADP-A2M4CD8) is being investigated in the SURPASS-3 Phase 2 clinical trial (NCT05601752) for the treatment of platinum-resistant ovarian cancer. Uza-cel received FDA RMAT designation in 2022 for the treatment of patients with platinum resistant ovarian cancer. The SURPASS-3 trial is currently enrolling patients.
- Cohorts in the Phase 1 SURPASS trial are ongoing for people with head & neck and urothelial (bladder) cancers with uza-cel in combination with standard of care checkpoint inhibitor therapy.
- 用於治療耐鉑卵巢癌的 SURPASS-3 二期臨床試驗（NCT05601752）正在研究Uzatresgene autoleucel（“uza-cel”，前身爲 ADP-A2M4CD8）。Uza-Cel於2022年獲得美國食品藥品管理局RMAT認證，用於治療耐鉑卵巢癌患者。SURPASS-3 試驗目前正在招收患者。
- 使用uza-cel與標準護理檢查點抑制劑療法聯合治療的頭頸癌和尿路上皮（膀胱）癌患者的1期SURPASS試驗的隊列正在進行中。
Preclinical pipeline
臨床前產品線
- IND-enabling studies are underway for ADP-600 (PRAME) and ADP-520 (CD70) programs.
- Wholly owned allogeneic pipeline advancing; process development in progress at Adaptimmune's allogeneic manufacturing facility in Milton Park, UK.
- ADP-600（PRAME）和 ADP-520（CD70）項目正在進行支持IND的研究。
- 全資異體管道正在推進；Adaptimmune位於英國米爾頓公園的異體制造工廠正在進行工藝開發。
-
Data presentation
- Poster presented by George Pope, Ph.D., Associate Director Preclinical Safety at Adaptimmune, entitled "Development and Preclinical Characterization of an Engineered T-Cell Therapy Targeting PRAME-Expressing Solid Tumors" at the American Society of Gene & Cell Therapy (ASGCT) Annual meeting
-
數據演示
- 由Adaptimmune臨床前安全副總監喬治·波普博士主辦的海報，標題爲”針對表達 PRAME 的實體瘤的工程化 T 細胞療法的開發和臨床前表徵“在美國基因與細胞療法學會（ASGCT）年會上
Corporate news
企業新聞
- As announced earlier today, Adaptimmune has secured up to $125 million in debt financing with Hercules Capital with the first tranche of $25 million available upon closing; and an additional $25 million available upon afami-cel approval
- Cash runway into late 2025 which includes current cash on hand, anticipated revenues from the launch of afami-cel, expected future income from partners and other non-dilutive capital sources including the Company's new debt facility with Hercules Capital
- Company announced that its strategic collaboration with Genentech was terminated
- 正如今天早些時候宣佈的那樣，Adaptimmune已向Hercules Capital獲得了高達1.25億美元的債務融資，第一筆2500萬美元在收盤時可用；另有2500萬美元將在afami-cel批准後可用
- 到2025年底的現金流，其中包括當前的手頭現金、啓動afami-cel的預期收入、來自合作伙伴的預期未來收入以及其他非稀釋性資本來源，包括公司與Hercules Capital的新債務額度
- 公司宣佈終止與基因泰克的戰略合作
Financial Results for the three months ended March 31, 2024
截至2024年3月31日的三個月的財務業績
- Cash / liquidity position: As of March 31, 2024, Adaptimmune had cash and cash equivalents of $140.7 million and Total Liquidity[1] of $143.7 million, compared to $144.0 million and $146.9 million respectively, as of December 31, 2023.
- Revenue: Revenue for the three months ended March 31, 2024, was $5.7 million compared to $47.6 million for the same period in 2023. Revenue has decreased in 2024, compared to the same period in 2023 primarily due to the termination of the Astellas collaboration in the first quarter of 2023, resulting in the remaining deferred income for the collaboration being recognized as revenue in March 2023.
- Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2024, were $35.2 million compared to $25.5 million for the same period in 2023. R&D expenses in the three months ended March 31, 2024 increased in employee-related costs and additional costs associated with lease properties following the acquisition of TCR2 in June 2023 and a decrease in offsetting reimbursements receivable for research and development tax and expenditure credits.
- General and administrative (G&A) expenses: G&A expenses for the three months ended March 31, 2024, were $19.7 million compared to $20.4 million for the same period in 2023. G&A expenses in the three months ended March 31, 2024 decreased due to restructuring and charges recognised in the first quarter of 2023 and a decrease in other corporate costs due to an increase in accounting, legal and professional fees incurred in relation to the TCR2 Therapeutics, Inc merger agreement that were not repeated in 2024, offset by an increase in depreciation due to leasehold improvements capitalised in 2023.
- Net loss/profit: Net loss attributable to holders of the Company's ordinary shares for the three months March 31, 2024, was $48.5 million ($(0.03) per ordinary share), compared to a profit of $1.0 million ($0.00 per ordinary share), for the same periods in 2023.
- 現金/流動性狀況： 截至2024年3月31日，Adaptimmune的現金及現金等價物爲1.407億美元，總流動性[1] 爲1.437億美元，而截至2023年12月31日，分別爲1.44億美元和1.469億美元。
- 收入：截至2024年3月31日的三個月，收入爲570萬美元，而2023年同期爲4,760萬美元。與2023年同期相比，2024年的收入有所下降，這主要是由於安斯泰來在2023年第一季度終止了合作，導致該合作的剩餘遞延收入在2023年3月被確認爲收入。
- 研發（R&D）費用： 截至2024年3月31日的三個月，研發費用爲3520萬美元，而2023年同期爲2550萬美元。在截至2024年3月31日的三個月中，研發費用增加了與員工相關的成本以及收購TCR後與租賃物業相關的額外成本2 2023年6月，研發稅收和支出抵免的抵消應收報銷額有所減少。
- 一般和行政（G&A）費用： 截至2024年3月31日的三個月，併購支出爲1,970萬美元，而2023年同期爲2,040萬美元。在截至2024年3月31日的三個月中，由於重組和2023年第一季度確認的費用，以及與TCR相關的會計、法律和專業費用增加導致其他公司成本的減少，G&A支出有所減少2 Therapeutics, Inc的合併協議在2024年沒有重複，但被2023年資本化租賃權改善導致的折舊增加所抵消。
- 淨虧損/利潤： 2024年3月31日這三個月，歸屬於公司普通股持有人的淨虧損爲4,850萬美元（每股普通股0.03美元），而2023年同期的利潤爲100萬美元（每股普通股0.00美元）。
Financial Guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with anticipated revenues from the launch of afami-cel, expected future income from partners and other non-dilutive capital sources including the Company's new debt facility with Hercules Capital announced earlier today, will fund the Company's current operations into late 2025, as further detailed in the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, to be filed with the Securities and Exchange Commission following this earnings release.
財務指導
該公司認爲，其現有現金、現金等價物和有價證券，加上推出afami-cel的預期收入、合作伙伴和其他非稀釋性資本來源的預期未來收入，包括公司今天早些時候宣佈的與Hercules Capital的新債務額度，將爲公司當前的業務提供到2025年底的資金，該公司將提交的截至2024年3月31日的三個月的10-Q表季度報告中進一步詳述美國證券交易委員會將關注這筆收益發布。
Today's Webcast Details
A live webcast and replay can be accessed at . Call in information is as follows: 1-800-806-5484 (US or Canada) or +416-340-2217 (International and additional options available HERE) and the passcode is 3025919#. Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
今天的網絡直播詳情
網絡直播和重播可在以下網址觀看 。 來電信息如下： 1-800-806-5484 （美國或加拿大）或 +416-340-2217 （此處提供國際和其他選項），密碼是 3025919 #。 來電者應在預定開始時間前 5-10 分鐘撥號，只需要求加入 Adaptimmune 通話即可。
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
關於 Adaptimmune
Adaptimmune 是一家處於臨床階段的生物製藥公司，專注於設計、開發和提供細胞療法，以改變癌症患者的生活。該公司獨特的工程化T細胞受體（TCR）平台使T細胞能夠靶向和消滅多種實體瘤類型的癌症。
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法》（PSLRA）所指的 “前瞻性陳述”。這些前瞻性陳述涉及某些風險和不確定性。此類風險和不確定性可能導致我們的實際結果與此類前瞻性陳述所示結果存在重大差異，包括但不限於：我們的產品開發活動和臨床試驗的成功、成本和時機，以及我們通過監管和商業化程序成功推進TCR候選療法的能力。要進一步描述可能導致我們的實際業績與這些前瞻性陳述中表達的業績存在重大差異的風險和不確定性以及與我們的總體業務相關的風險，請參閱我們向美國證券交易委員會提交的截至2023年12月31日止年度的10-K表年度報告、10-Q表季度報告、8-K表最新報告以及向美國證券交易委員會提交的其他文件。本新聞稿中包含的前瞻性陳述僅代表截至聲明發表之日，我們沒有義務更新此類前瞻性陳述以反映隨後的事件或情況。
Total Liquidity (a non-GAAP financial measure)
Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands):
總流動性（非公認會計准則財務指標）
總流動性（非公認會計准則財務指標）是現金和現金等價物以及有價證券（可供出售的債務證券）的總和。這些組成部分分別出現在簡明的合併資產負債表中。與總流動性最直接可比的美國公認會計准則財務指標是簡明合併財務報表中報告的現金和現金等價物，該財務報表與總流動性對賬如下（以千計）：
| March 31, | December 31, | ||||||||
| 2024 | 2023 | ||||||||
| Cash and cash equivalents | $ | 140,670 | $ | 143,991 | |||||
| Marketable securities - available-for-sale debt securities | 2,982 | 2,947 | |||||||
| Total Liquidity | $ | 143,652 | $ | 146,938 | |||||
| 3月31日 | 十二月 31, | ||||||||
| 2024 | 2023 | ||||||||
| 現金和現金等價物 | $ | 140,670 | $ | 143,991 | |||||
| 有價證券——可供出售的債務證券 | 2,982 | 2,947 | |||||||
| 總流動性 | $ | 143,652 | $ | 146,938 | |||||
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage.
公司認爲，總流動性的列報爲投資者提供了有用的信息，因爲管理層對總流動性的審查是其評估整體償付能力和流動性、財務靈活性、資本狀況和槓桿率的一部分。
Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data)
簡明合併運營報表
（未經審計，以千計，每股數據除外）
| Three months ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 5,678 | $ | 47,601 | ||||
| Operating expenses | ||||||||
| Research and development | (35,207) | (25,548) | ||||||
| General and administrative | (19,732) | (20,397) | ||||||
| Total operating expenses | (54,939) | (45,945) | ||||||
| Operating (loss)/profit | (49,261) | 1,656 | ||||||
| Interest income | 1,345 | 676 | ||||||
| Other income (expense), net | (61) | (671) | ||||||
| (Loss)/profit before income tax expense | (47,977) | 1,661 | ||||||
| Income tax expense | (526) | (625) | ||||||
| Net (loss)/profit attributable to ordinary shareholders | $ | (48,503) | $ | 1,036 | ||||
| Net (loss)/profit per ordinary share | ||||||||
| Basic | $ | (0.03) | $ | 0.00 | ||||
| Diluted | $ | (0.03) | $ | 0.00 | ||||
| Weighted average shares outstanding: | ||||||||
| Basic | 1,451,241,661 | 991,330,402 | ||||||
| Diluted | 1,451,241,661 | 1,000,276,615 | ||||||
| 三個月已結束 | ||||||||
| 3月31日 | ||||||||
| 2024 | 2023 | |||||||
| 收入 | $ | 5,678 | $ | 47,601 | ||||
| 運營費用 | ||||||||
| 研究和開發 | (35,207) | (25,548) | ||||||
| 一般和行政 | (19,732) | (20,397) | ||||||
| 運營費用總額 | (54,939) | (45,945) | ||||||
| 營業（虧損）/利潤 | (49,261) | 1,656 | ||||||
| 利息收入 | 1,345 | 676 | ||||||
| 其他收入（支出），淨額 | (61) | (671) | ||||||
| 所得稅支出前（虧損）/利潤 | (47,977) | 1,661 | ||||||
| 所得稅支出 | (526) | (625) | ||||||
| 歸屬於普通股股東的淨（虧損）/利潤 | $ | (48,503) | $ | 1,036 | ||||
| 每股普通股淨（虧損）/利潤 | ||||||||
| 基本 | $ | (0.03) | $ | 0.00 | ||||
| 稀釋 | $ | (0.03) | $ | 0.00 | ||||
| 已發行股票的加權平均值： | ||||||||
| 基本 | 1,451,241,661 | 991,330,402 | ||||||
| 稀釋 | 1,451,241,661 | 1,000,276,615 | ||||||
Condensed Consolidated Balance Sheets
(unaudited, in thousands, except share data)
簡明合併資產負債表
（未經審計，以千計，股票數據除外）
| March 31, | December 31, | |||||||||
| 2024 | 2023 | |||||||||
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | $ | 140,670 | $ | 143,991 | ||||||
| Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0 | 2,982 | 2,947 | ||||||||
| Accounts receivable, net of allowance for expected credit losses of $0 and $0 | 8,404 | 821 | ||||||||
| Other current assets and prepaid expenses | 34,847 | 59,793 | ||||||||
| Total current assets | 186,903 | 207,552 | ||||||||
| Restricted cash | 2,858 | 3,026 | ||||||||
| Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220 | 19,434 | 20,762 | ||||||||
| Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020 | 48,291 | 50,946 | ||||||||
| Intangible assets, net of accumulated amortization of $5,198 and $5,155 | 524 | 330 | ||||||||
| Total assets | $ | 258,010 | $ | 282,616 | ||||||
| Liabilities and stockholders' equity | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable | $ | 6,587 | $ | 8,128 | ||||||
| Operating lease liabilities, current | 5,250 | 5,384 | ||||||||
| Accrued expenses and other current liabilities | 23,050 | 30,303 | ||||||||
| Deferred revenue, current | 31,524 | 28,973 | ||||||||
| Total current liabilities | 66,411 | 72,788 | ||||||||
| Operating lease liabilities, non-current | 18,442 | 19,851 | ||||||||
| Deferred revenue, non-current | 147,365 | 149,060 | ||||||||
| Other liabilities, non-current | 1,417 | 1,404 | ||||||||
| Total liabilities | 233,635 | 243,103 | ||||||||
| Stockholders' equity | ||||||||||
| Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding) | 2,081 | 1,865 | ||||||||
| Additional paid in capital | 1,096,690 | 1,064,569 | ||||||||
| Accumulated other comprehensive loss | (2,720) | (3,748) | ||||||||
| Accumulated deficit | (1,071,676) | (1,023,173) | ||||||||
| Total stockholders' equity | 24,375 | 39,513 | ||||||||
| Total liabilities and stockholders' equity | $ | 258,010 | $ | 282,616 | ||||||
| 3月31日 | 十二月 31, | |||||||||
| 2024 | 2023 | |||||||||
| 資產 | ||||||||||
| 流動資產 | ||||||||||
| 現金和現金等價物 | $ | 140,670 | $ | 143,991 | ||||||
| 有價證券——扣除0美元和0美元的預期信貸損失備抵後的可供出售債務證券（攤銷成本爲2,981美元和2,940美元） | 2,982 | 2,947 | ||||||||
| 應收賬款，扣除0美元和0美元的預期信貸損失備抵金 | 8,404 | 821 | ||||||||
| 其他流動資產和預付費用 | 34,847 | 59,793 | ||||||||
| 流動資產總額 | 186,903 | 207,552 | ||||||||
| 受限制的現金 | 2,858 | 3,026 | ||||||||
| 經營租賃使用權資產，扣除14,381美元和13,220美元的累計攤銷額 | 19,434 | 20,762 | ||||||||
| 不動產、廠房和設備，扣除48,445美元和46,020美元的累計折舊 | 48,291 | 50,946 | ||||||||
| 無形資產，扣除5,198美元和5,155美元的累計攤銷額 | 524 | 330 | ||||||||
| 總資產 | $ | 258,010 | $ | 282,616 | ||||||
| 負債和股東權益 | ||||||||||
| 流動負債 | ||||||||||
| 應付賬款 | $ | 6,587 | $ | 8,128 | ||||||
| 經營租賃負債，當前 | 5,250 | 5,384 | ||||||||
| 應計費用和其他流動負債 | 23,050 | 30,303 | ||||||||
| 遞延收入，當前 | 31,524 | 28,973 | ||||||||
| 流動負債總額 | 66,411 | 72,788 | ||||||||
| 經營租賃負債，非流動 | 18,442 | 19,851 | ||||||||
| 遞延收入，非當期 | 147,365 | 149,060 | ||||||||
| 其他非流動負債 | 1,417 | 1,404 | ||||||||
| 負債總額 | 233,635 | 243,103 | ||||||||
| 股東權益 | ||||||||||
| 普通股——普通股面值0.001英鎊，已授權1,702,760,280股，已發行和流通1,532,974,878股（2023年：授權1,702,760,280股，已發行和流通1,363,008,102股） | 2,081 | 1,865 | ||||||||
| 額外已繳資本 | 1,096,690 | 1,064,569 | ||||||||
| 累計其他綜合虧損 | (2,720) | (3,748) | ||||||||
| 累計赤字 | (1,071,676) | (1,023,173) | ||||||||
| 股東權益總額 | 24,375 | 39,513 | ||||||||
| 負債和股東權益總額 | $ | 258,010 | $ | 282,616 | ||||||
Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
簡明合併現金流量表
（未經審計，以千計）
| Three months ended | |||||||||
| March 31, | |||||||||
| 2024 | 2023 | ||||||||
| Cash flows from operating activities | |||||||||
| Net (loss)/profit | $ | (48,503) | $ | 1,036 | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
| Depreciation | 2,771 | 1,659 | |||||||
| Amortization | 59 | 186 | |||||||
| Share-based compensation expense | 3,102 | 1,676 | |||||||
| Unrealized foreign exchange losses | 305 | 563 | |||||||
| (Accretion)/amortization on available-for-sale debt securities | (23) | 112 | |||||||
| Other | (19) | 134 | |||||||
| Changes in operating assets and liabilities: | |||||||||
| Increase in receivables and other operating assets | 15,620 | 3,683 | |||||||
| (Decrease)/increase in payables and other current liabilities | (7,650) | 21 | |||||||
| Decrease/(increase) in deferred revenue | 2,388 | (46,353) | |||||||
| Net cash used in operating activities | (31,950) | (37,283) | |||||||
| Cash flows from investing activities | |||||||||
| Acquisition of property, plant and equipment | (102) | (2,349) | |||||||
| Acquisition of intangible assets | (256) | (173) | |||||||
| Maturity or redemption of marketable securities | — | 50,863 | |||||||
| Net cash (used in)/provided by investing activities | (358) | 48,341 | |||||||
| Cash flows from financing activities | |||||||||
| Proceeds from issuance of common stock from offerings, net of commissions and issuance costs | 29,161 | 188 | |||||||
| Proceeds from exercise of stock options | 74 | 8 | |||||||
| Net cash provided by financing activities | 29,235 | 196 | |||||||
| Effect of currency exchange rate changes on cash, cash equivalents and restricted cash | (416) | 588 | |||||||
| Net (decrease)/increase in cash, cash equivalents and restricted cash | (3,489) | 11,842 | |||||||
| Cash, cash equivalents and restricted cash at start of period | 147,017 | 109,602 | |||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 143,528 | $ | 121,444 | |||||
| 三個月已結束 | |||||||||
| 3月31日 | |||||||||
| 2024 | 2023 | ||||||||
| 來自經營活動的現金流 | |||||||||
| 淨（虧損）/利潤 | $ | (48,503) | $ | 1,036 | |||||
| 爲使淨虧損與經營活動中使用的淨現金相一致而進行的調整： | |||||||||
| 折舊 | 2,771 | 1,659 | |||||||
| 攤銷 | 59 | 186 | |||||||
| 基於股份的薪酬支出 | 3,102 | 1,676 | |||||||
| 未實現的外匯損失 | 305 | 563 | |||||||
| 可供出售債務證券的（增值）/攤銷 | (23) | 112 | |||||||
| 其他 | (19) | 134 | |||||||
| 運營資產和負債的變化： | |||||||||
| 應收賬款和其他運營資產的增加 | 15,620 | 3,683 | |||||||
| 應付賬款和其他流動負債 (減少) /增加 | (7,650) | 21 | |||||||
| 遞延收入減少/（增加） | 2,388 | (46,353) | |||||||
| 用於經營活動的淨現金 | (31,950) | (37,283) | |||||||
| 來自投資活動的現金流 | |||||||||
| 購置不動產、廠房和設備 | (102) | (2,349) | |||||||
| 收購無形資產 | (256) | (173) | |||||||
| 有價證券的到期或贖回 | — | 50,863 | |||||||
| 淨現金（用於）/由投資活動提供 | (358) | 48,341 | |||||||
| 來自融資活動的現金流 | |||||||||
| 發行普通股的收益，扣除佣金和發行成本 | 29,161 | 188 | |||||||
| 行使股票期權的收益 | 74 | 8 | |||||||
| 融資活動提供的淨現金 | 29,235 | 196 | |||||||
| 貨幣匯率變動對現金、現金等價物和限制性現金的影響 | (416) | 588 | |||||||
| 現金、現金等價物和限制性現金淨額（減少）/增加 | (3,489) | 11,842 | |||||||
| 期初的現金、現金等價物和限制性現金 | 147,017 | 109,602 | |||||||
| 期末現金、現金等價物和限制性現金 | $ | 143,528 | $ | 121,444 | |||||
Adaptimmune Contact
適應免疫接點
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
投資者關係
Juli P. Miller，博士-公司事務和投資者關係副總裁
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
媒體關係
達娜·林奇，企業傳播高級董事
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
[1] Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below
[1] 總流動性是一種非公認會計准則財務指標，以下是根據公認會計原則編制的最直接可比的財務指標進行解釋和核對
譯文內容由第三人軟體翻譯。